Outcomes of Relapsed Core Binding Factor Acute Myeloid Leukemia: an MD Anderson Experience

CBF-AML, which accounts for ∼20% of AML, is defined by presence of t(8;21)(q22;q22) [t(8;21)] and inv(16)(p13q22) or t(16;16)(p13;q22) [inv(16)]. Although CBF-AML is considered a favorable cytogenetic subset, many patients experience relapse, and it is critical to identify features that can predict patient outcomes after rel apse.

Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Maliha Khan, Jorge Cortes, Wei Qiao, Mohanad Alzubaidi, Sherry Pierce, Rebacca Slack, Farhad Ravandi, Hagop Kantarjian, Gautam Borthakur Source Type: research